Testing upadacitinib for EoE that doesn't respond to steroids
Treatments studied
Part of Blood & lymphatic, Digestive system, Immune system & allergy clinical trials.
This study tests a pill called upadacitinib (a JAK inhibitor) in people with eosinophilic esophagitis (EoE) that hasn't improved with swallowed steroids. It aims to see if the drug can reduce inflammation and symptoms in the esophagus when added to your current steroid treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 65 years old.
- You need a confirmed EoE diagnosis (based on medical guidelines).
- You must be currently using a swallowed (topical) steroid for EoE, like budesonide or fluticasone, for at least 8 weeks and willing to keep the same dose throughout the study.
- Despite the steroid, your last endoscopy must show active EoE (≥15 eosinophils per high-power field) and you must have symptoms like trouble swallowing, heartburn, or chest pain in the 4 weeks before that endoscopy.
- You must be willing to continue all current EoE treatments (like PPIs or diet changes) and be able to swallow a pill.
- You must be able to read and understand English and give consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an intervention meant to improve how well adults with eosinophilic esophagitis (EoE) follow their ongoing treatment plan. It may help you stay on your medicine and get better symptom control by making adherence easier.
This Phase 1/2 study tests EP-104GI in adults with eosinophilic esophagitis (EoE), a condition where certain immune cells cause inflammation in the food pipe. It may help improve symptoms and inflammation, and the study also includes a part where people who do well can switch to the active drug.
This study looks at how the immune system and the esophageal barrier function in people with eosinophilic esophagitis (EoE) compared to those without. It involves taking biopsies during an upper endoscopy to understand the disease better. The results may help improve treatments for EoE.
This study compares two medicines—Eohilia (an oral steroid) and Dupixent (an injectable biologic)—to see which one better helps widen the esophagus in people with eosinophilic esophagitis (EoE). It may help you if you have active EoE and are looking for a new treatment option.
This study compares two treatments for EoE that has caused narrowing in the esophagus: dupilumab (a biologic injection) versus a topical corticosteroid (a swallowed steroid). It aims to see which works better for teens and young adults to improve swallowing and reduce inflammation.
This study compares the effectiveness of a pill (upadacitinib) with several biologic injections (biologics are medicines that target specific parts of the immune system) in controlling moderate-to-severe atopic dermatitis (eczema). The goal is to see which treatment helps people achieve minimal disease activity, meaning their eczema is under good control.
Hear when a new Eosinophilic Esophagitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.